Loading...
•
Mar 31, 2022
Merck Q1 2022 Earnings Report
Merck successfully delivered across key strategic priorities, achieving strong top- and bottom-line growth.
Key Takeaways
Merck reported strong first-quarter results, driven by clinical advancements and commercial execution. Total sales increased, led by oncology, vaccines, and hospital acute care products, with significant contributions from KEYTRUDA and GARDASIL. The company is raising and narrowing its full-year guidance for revenues and EPS.
First-quarter pharmaceutical sales increased 53% to $14.1 billion.
LAGEVRIO sales totaled $3.2 billion for the first quarter.
KEYTRUDA sales rose 23% to $4.8 billion.
GARDASIL and GARDASIL 9 sales grew 59% to $1.5 billion.
Merck
Merck
Merck Revenue by Segment
Revenue by Segment
Pharmaceutical Revenue
CapyFin.comAnimal Health Revenue
CapyFin.com Forward Guidance
Merck is raising and narrowing its full-year guidance for revenues and EPS. The company now expects sales growth of 17% to 19% in 2022, with full-year revenue estimated to be between $56.9 billion and $58.1 billion. Full-year 2022 GAAP EPS is expected to be between $5.90 and $6.02, and non-GAAP EPS is expected to be between $7.24 and $7.36.
Positive Outlook
- Strong global underlying demand across key growth pillars.
- Sales growth expected between 17% and 19%.
- Full-year revenue estimated between $56.9 billion and $58.1 billion.
- Full-year GAAP EPS range raised to $5.90 to $6.02.
- Full-year non-GAAP EPS range raised to $7.24 to $7.36.
Challenges Ahead
- Negative impact from foreign exchange of just over 2% on revenues.
- Negative impact from foreign exchange of approximately 2%, or $0.11, on non-GAAP EPS.
- Includes expected sales of $5.0 billion to $5.5 billion from LAGEVRIO.
- LAGEVRIO profits are shared equally with Ridgeback, impacting cost of sales.
- The financial outlook does not assume any significant expenses or charges from transactions that would have been previously excluded from non-GAAP results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income